Table 3.
Current status of 11 aptamers undergoing clinical trials.
| Aptamer | Target | Conditions | Current Status | Reference |
|---|---|---|---|---|
| Pegaptanib (Macugen) | VEGF | Age related macular degeneration/diabetic macular edema/proliferative diabetic | FDA approved | [21] |
| NU172 | Thrombin | Heart disease | Phase II | NCT00808964 * |
| AS1411 (AGRO-100) | Nucleolin | Renal cell carcinoma/non-small cell lung cancer | Awaiting Phase III | [103] |
| ARC1779 | A1domain of von Willebrand factor | von Willebrand‘s disease | Awaiting Phase III | NCT00742612 * |
| ARC1905 | Complement component 5 (C5) | Neovascular age related macular degeneration | Phase II/III, (recruiting) | NCT02686658 * |
| ARC19499 (BAX499) | Tissue factor pathway inhibitor (TFPI) | Hemophilia | Phase I/II | NCT01191372 * |
| REG1 (RB006 plus RB007) | Coagulation factor IXa | Coronary artery disease | Phase III | [102] |
| NOX-A12 | Angiogenic chemokine (C-X-C motif) ligand 12 (CXCL1) | Tumor | Phase II | NCT01486797 * |
| NOX-E36 | Pro-inflammatory chemokine C-C motif-ligand 2(CCL2) | Type II diabetes mellitus/Renal impairment/nephropathy/lupus nephritis | Phase II | NCT01547897 * |
| NOX-H94 | Hepcidin | Anemia of chronic disease | Phase II | NCT01691040 * |
| E10030 | Platelet-derived growth factor (PDGF) | Neovascular age related macular degeneration | Awaiting Phase III | NCT01944839 * |
* clinical trial number.